23.61

4.95% -1.23

Syndax Pharmaceuticals Inc (SNDX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$24.84

Aprire:

$24.79

Volume 24 ore:

2.10M

Relative Volume:

1.12

Capitalizzazione di mercato:

$2.09B

Reddito:

$217.42M

Utile/perdita netta:

$-243.25M

Rapporto P/E:

-8.4466

EPS:

-2.7952

Flusso di cassa netto:

$-278.35M

1 W Prestazione:

+8.20%

1M Prestazione:

+34.30%

6M Prestazione:

+12.43%

1 anno Prestazione:

+140.43%

Intervallo 1D:

$23.01

$24.79

Intervallo di 1 settimana:

$21.24

$25.24

Portata 52W:

$9.03

$25.59

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Nome

Syndax Pharmaceuticals Inc

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

781-419-1400

Indirizzo

730 THIRD AVENUE, NEW YORK, MA

Dipendente

298

Cinguettio

@syndax

Prossima data di guadagno

2026-08-03

Ultimi documenti SEC

SNDX's Discussions on Twitter

Compare SNDX vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SNDX Syndax Pharmaceuticals Inc	23.61	2.09B	217.42M	-243.25M	-278.35M	-2.7952
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-10-16	Ripresa	H.C. Wainwright	Buy
2025-09-10	Ripresa	Stifel	Buy
2025-09-04	Ripresa	Guggenheim	Buy
2025-08-05	Reiterato	BTIG Research	Buy
2025-07-10	Iniziato	Goldman	Buy
2024-10-24	Iniziato	UBS	Buy
2024-06-28	Iniziato	Jefferies	Buy
2024-01-31	Downgrade	Scotiabank	Sector Outperform → Sector Perform
2023-12-22	Iniziato	Mizuho	Buy
2023-10-25	Iniziato	BofA Securities	Buy
2023-10-11	Iniziato	Goldman	Buy
2023-07-27	Iniziato	Scotiabank	Sector Outperform
2023-07-11	Iniziato	Guggenheim	Buy
2023-04-17	Ripresa	BTIG Research	Buy
2023-01-31	Iniziato	Stifel	Buy
2023-01-03	Iniziato	JP Morgan	Overweight
2022-07-28	Ripresa	B. Riley Securities	Buy
2022-04-11	Iniziato	H.C. Wainwright	Buy
2022-02-15	Iniziato	Goldman	Buy
2021-06-04	Ripresa	Robert W. Baird	Outperform
2021-05-25	Iniziato	Citigroup	Buy
2021-02-18	Iniziato	B. Riley Securities	Buy
2020-12-03	Iniziato	Stifel	Buy
2020-05-22	Aggiornamento	Citigroup	Neutral → Buy
2020-05-22	Downgrade	H.C. Wainwright	Buy → Neutral
2020-05-18	Downgrade	Citigroup	Buy → Neutral
2020-05-11	Reiterato	H.C. Wainwright	Buy
2020-03-04	Iniziato	Barclays	Overweight
2020-01-13	Reiterato	H.C. Wainwright	Buy
2019-03-08	Reiterato	H.C. Wainwright	Buy
2019-01-04	Iniziato	Robert W. Baird	Outperform
2018-01-05	Iniziato	B. Riley FBR, Inc.	Buy
2017-03-16	Iniziato	FBR & Co.	Outperform
2017-03-02	Iniziato	Instinet	Buy
2016-10-07	Iniziato	Guggenheim	Buy
2016-03-28	Iniziato	Citigroup	Buy
2016-03-28	Iniziato	JMP Securities	Mkt Outperform
2016-03-28	Iniziato	Morgan Stanley	Overweight

Mostra tutto

Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie

Jul 09, 2026

Technical Reactions to SNDX Trends in Macro Strategies - Stock Traders Daily

Jul 09, 2026

Form 4 Syndax Pharmaceuticals For: 9 July By Investing.com - Investing.com Nigeria

Jul 09, 2026

Syndax CEO Michael Metzger sells $784,776 in company stock - Investing.com

Jul 09, 2026

Syndax (SNDX) CEO Metzger exercises options and sells 32,375 shares under 10b5-1 plan - Stock Titan

Jul 09, 2026

Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing - Moomoo

Jul 09, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 32,375 Shares - MarketBeat

Jul 09, 2026

Syndax CEO Michael Metzger sells $784,776 in company stock By Investing.com - Investing.com Canada

Jul 09, 2026

Jul 08, 2026

Form 144 Syndax Pharmaceuticals For: 8 July By Investing.com - Investing.com Nigeria

Jul 08, 2026

SNDX insider files to sell 32,375 shares (NASDAQ: SNDX) - Stock Titan

Jul 08, 2026

Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next - simplywall.st

Jul 08, 2026

Jul 07, 2026

Syndax Pharmaceuticals holds steady as investors await a fresh catalyst - AD HOC NEWS

Jul 07, 2026

Jul 06, 2026

SG Americas Securities LLC Has $900,000 Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Jul 06, 2026

Jul 04, 2026

Syndax Pharmaceuticals (SNDX) Reports Strong Revuforj Data, Is The Upside Already Priced In? - Sahm

Jul 04, 2026

Jul 01, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Jul 01, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Jul 01, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Draws Fresh Market Attention - Kalkine Media

Jul 01, 2026

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Jul 01, 2026

Jun 30, 2026

Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates? - Insider Monkey

Jun 30, 2026

Purchase/sale of business (net) of Syndax Pharmaceuticals Inc – SWB:1T3 - TradingView

Jun 30, 2026

Jun 29, 2026

Price to sales forward of Syndax Pharmaceuticals Inc – MUN:1T3 - TradingView

Jun 29, 2026

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com

Jun 29, 2026

Does Syndax Pharmaceuticals’ (SNDX) Russell Value Index Exit Quietly Recast Its Liquidity And Risk Narrative? - simplywall.st

Jun 29, 2026

Enterprise value to revenue forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView

Jun 29, 2026

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Enterprise value to EBITDA forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView

Jun 28, 2026

Trading the Move, Not the Narrative: (SNDX) Edition - Stock Traders Daily

Jun 28, 2026

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 2000 Value Benchmark - marketscreener.com

Jun 28, 2026

Price to earnings forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView

Jun 28, 2026

Price to earnings forward of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView

Jun 28, 2026

Syndax Pharmaceuticals (SNDX) Surges 7.6% as Momentum Builds Past Key SupportButterfly Setup - dars.gov.et

Jun 28, 2026

Enterprise value to revenue forward of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView

Jun 28, 2026

Price to book forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView

Jun 28, 2026

Jun 27, 2026

Price to sales forward of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView

Jun 27, 2026

Price to book forward of Syndax Pharmaceuticals Inc – MUN:1T3 - TradingView

Jun 27, 2026

Jun 26, 2026

Syndax Pharmaceuticals stock jumps 7.57% as Syndax applauds Dana-Farber's Dr. Armstrong award - Traders Union

Jun 26, 2026

Syndax Pharmaceuticals Inc Actuals & Estimates (DUS:1T3) - TradingView

Jun 26, 2026

Jun 25, 2026

SNDX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Jun 25, 2026

1T3 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 23, 2026

3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal - AOL.com

Jun 23, 2026

Syndax Pharmaceuticals (SNDX) Stock Could Be 51.9% Undervalued After SAVE Trial Data - Sahm

Jun 23, 2026